In particular, Siglec-9 interacts with sialic acids on cancer cells (i.e., with MUC1, a high molecular weight glycoprotein expressed on adenocarcinoma cells including breast cancer) leading to immune suppression [152]. This evidence concerns the gene MUC1 and breast carcinoma.